The KP⁷ Formula

PDE5 inhibition and eNOS activation: dual vascular pathway. Prevents cGMP degradation while simultaneously upregulating nitric oxide production in the vascular endothelium. The result is a sustained, progressive pump that builds across the session rather than peaking and declining.

The hero compound. No other UK pre-workout is built around this ingredient. The dual vascular mechanism produces a qualitatively different training experience.

200mg at 5% PMFs delivers 10mg of active PMFs, at the upper end of the clinically studied range (180mg in the primary human trial) without exceeding it.

Converted to L-arginine in the kidney, bypassing hepatic first-pass extraction. Arginine is the substrate for eNOS, increasing upstream NO production.

Mechanistically complementary to Kaempferia parviflora. KP acts on the downstream cGMP signal; Citrulline increases the upstream NO substrate that generates it. Together they create a synergistic vascular effect.

4,000mg exceeds the clinically studied minimum effective dose (typically 3,000–6,000mg in published trials). A full clinical dose, not a token label dose.

Adenosine receptor antagonism in the central nervous system. Blocks the fatigue signal, producing alertness and enhanced focus. Does not directly affect the vascular mechanism.

Clean CNS activation without the crash architecture of high-dose caffeine. Paired 1:1 with L-Theanine, this is the most evidence-backed combination for sustained cognitive performance without jitteriness.

200mg is deliberate. The category norm of 300–400mg produces a sharper spike and a correspondingly sharper crash. 200mg + 200mg L-Theanine produces a flatter, longer, more functional energy curve.

Modulates GABA-ergic pathways, attenuating anxiety and jitteriness without sedation. Increases alpha-wave activity associated with relaxed alertness. Works synergistically with caffeine.

Makes caffeine work better. The 1:1 combination is one of the most replicated findings in cognitive performance research: sharper focus, less anxiety, no crash.

200mg, matched 1:1 with caffeine. This ratio is consistent with the evidence base showing the optimal attenuating effect on caffeine-induced anxiety while preserving its alertness benefits.

Functions as both a methyl donor in one-carbon metabolism (supporting creatine synthesis pathways) and a cellular osmolyte, helping muscle cells maintain hydration status under load.

Power output and endurance support. Betaine's evidence base is strongest at 2,500mg over multi-week use, with improvements in power output and favourable body composition effects.

2,500mg is the dose used in most published trials. This is not a label dose. It is the full clinical dose.

Adaptogenic compound that modulates the HPA axis response to physical stress. Evidence suggests reduced perceived exertion and improved fatigue resistance during prolonged physical effort.

Fatigue support. As the session progresses and KP's vascular effect is building, Rhodiola helps maintain output quality in the later sets.

150mg at the clinical standardisation (3% rosavins / 1% salidroside). This matches the extract specification used in the key trials. Off-specification extracts cannot be compared to this evidence.

Inhibits cytochrome P450 3A4 and P-glycoprotein, the primary enzymes responsible for first-pass clearance of many compounds. Increases bioavailability of co-administered actives.

Absorption. The Kaempferia parviflora PMFs are lipophilic and subject to first-pass extraction. Bioperine maximises the delivery of active compounds from the full formula.

5mg at 95% piperine is the standard clinical dose. This is the established effective amount for bioavailability enhancement.